论文部分内容阅读
目的探讨89锶(89Sr)联合内分泌疗法治疗前列腺癌骨转移性疼痛的疗效。方法将64例确诊为前列腺癌且具有骨转移病灶并伴有疼痛的患者随机分为两组:89Sr联合内分泌治疗组42例,单纯采用内分泌治疗组26例,观察治疗后两组的止痛疗效、骨转移灶变化、血常规及生化指标的变化。结果治疗前两组患者的疼痛级数间差异无显著性意义(P>0.05)。治疗后联合治疗组患者疼痛级数较单纯内分泌组显著降低(P<0.05);联合治疗组患者骨转移病灶治疗有效率较单纯内分泌组显著升高(P<0.05)。结论 89Sr联合内分泌疗法能迅速有效地缓解前列腺癌骨转移疼痛,使骨转移病灶缩小或消失,副作用小,其疗效明显优于单纯内分泌疗法。
Objective To investigate the effect of 89Sr combined with endocrine therapy on bone metastatic pain of prostate cancer. Methods Sixty-four patients diagnosed as prostate cancer with bone metastases and pain were randomly divided into two groups: 42 patients in the 89Sr combined with endocrine therapy group and 26 patients in the endocrine therapy group alone. The analgesic effects, Changes in bone metastases, blood and biochemical changes. Results There was no significant difference in the grade of pain between the two groups before treatment (P> 0.05). After treatment, the pain scores of combined treatment group were significantly lower than those of pure endocrine group (P <0.05). The effective rate of bone metastases in combination therapy group was significantly higher than that in endocrine group (P <0.05). Conclusion 89Sr combined with endocrine therapy can quickly and effectively relieve the pain of bone metastases of prostate cancer, reduce or disappear the bone metastases, and reduce the side effects. The curative effect is better than that of pure endocrine therapy.